Regulation of Vascular Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG

Gynecologic Oncology

Volumn 113, Issue 3, 2009, Pages 374-378

  Dann, James M ^a,b   Sykes, Peter H ^a   Mason, Drusilla R ^b   Evans, John J ^a,c,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d MACDIARMID INSTITUTE FOR ADVANCED MATERIALS AND NANOTECHNOLOGY   (New Zealand)

Author keywords

Angiogenesis; EGCG; Endometrial carcinoma; Hypoxia; Resveratrol; VEGF

Indexed keywords

EPIGALLOCATECHIN GALLATE; RESVERATROL; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYSTERECTOMY; PRIORITY JOURNAL; TUMOR CELL;

ANTICARCINOGENIC AGENTS; CATECHIN; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; STILBENES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349187263     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.014     Document Type: Article

References (33)

1. Tan C., de Noronha R.G., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65 2 (2005 Jan 15) 605-612
2. Park E.J., Kong D., Fisher R., Cardellina J., Shoemaker R.H., and Melillo G. Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5 16 (2006 Aug) 1847-1853
3. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 15 (2002 Aug 1) 4316-4324
4. Dai M., Cui P., Yu M., Han J., Li H., and Xiu R. Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J. Pineal Res. 44 2 (2008 Mar) 121-126
5. Park S.Y., Jeong K.J., Lee J., Yoon D.S., Choi W.S., Kim Y.K., et al. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 258 1 (2007 Dec 8) 63-69
6. Kazi A.A., and Koos R.D. Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 148 5 (2007 May) 2363-2374
7. Wong C., Wellman T.L., and Lounsbury K.M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. 91 3 (2003 Dec) 513-517
8. Fedele A.O., Whitelaw M.L., and Peet D.J. Regulation of gene expression by the hypoxia-inducible factors. Mol. Interv. 2 4 (2002 Jul) 229-243
9. Bracken C.P., Fedele A.O., Linke S., Balrak W., Lisy K., Whitelaw M.L., et al. Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281 32 (2006 Aug 11) 22575-22585
10. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 1 (2001 Oct 5) 43-54
11. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 5516 (2001 Apr 20) 468-472
12. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 5545 (2001 Nov 9) 1337-1340
13. Stroka D.M., Burkhardt T., Desbaillets I., Wenger R.H., Neil D.A., Bauer C., et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 15 13 (2001 Nov) 2445-2453
14. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 6733 (1999 May 20) 271-275
15. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224 3 (2007 Nov 1) 274-283
16. Tang X., Zhang Q., Nishitani J., Brown J., Shi S., and Le A.D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 13 9 (2007 May 1) 2568-2576
17. Zhang Q., Tang X., Lu Q.Y., Zhang Z.F., Brown J., and Le A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 4 10 (2005 Oct) 1465-1474
18. Jung Y.D., and Ellis L.M. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int. J. Exp. Pathol. 82 6 (2001 Dec) 309-316
19. Fassina G., Vene R., Morini M., Minghelli S., Benelli R., Noonan D.M., et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res. 10 14 (2004 Jul 15) 4865-4873
20. Gao Y.T., McLaughlin J.K., Blot W.J., Ji B.T., Dai Q., and Fraumeni Jr. J.F. Reduced risk of esophageal cancer associated with green tea consumption. J. Natl. Cancer Inst. 86 11 (1994 Jun 1) 855-858
21. Zhang M., Binns C.W., and Lee A.H. Tea consumption and ovarian cancer risk: a case-control study in China. Cancer Epidemiol. Biomark. Prev. 11 8 (2002 Aug) 713-718
22. Inoue M., Tajima K., Hirose K., Hamajima N., Takezaki T., Kuroishi T., et al. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 9 2 (1998 Mar) 209-216
23. Kono S., Ikeda M., Tokudome S., and Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn. J. Cancer Res. 79 10 (1988 Oct) 1067-1074
24. Ji B.T., Chow W.H., Hsing A.W., McLaughlin J.K., Dai Q., Gao Y.T., et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 70 3 (1997 Jan 27) 255-258
25. Nakachi K., Suemasu K., Suga K., Takeo T., Imai K., and Higashi Y. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn. J. Cancer Res. 89 3 (1998 Mar) 254-261
26. Shu B., Yang W.W., and Yang H.T. Expression pattern of E2F6 in physical and chemical hypoxia-induced apoptosis. Sheng Li Xue Bao 60 1 (2008 Feb 25) 1-10
27. Cao Z., Fang J., Xia C., Shi X., and Jiang B.H. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 10 15 (2004 Aug 1) 5253-5263
28. Ozbudak I.H., Karaveli S., Simsek T., Erdogan G., and Pestereli E. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol. Oncol. 108 3 (2008 Mar) 603-608
29. Kimbro K.S., and Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 13 3 (2006 Sep) 739-749
30. La Vecchia C., and Bosetti C. Diet and cancer risk in Mediterranean countries: open issues. Public Health Nutr. 9 8A (2006 Dec) 1077-1082
31. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., and Le A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 5 5 (2006 May) 1227-1238
32. Thomas R., and Kim M.H. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem. Biophys. Res. Commun. 334 2 (2005 Aug 26) 543-548
33. Zhou Y.D., Kim Y.P., Li X.C., Baerson S.R., Agarwal A.K., Hodges T.W., et al. Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. 67 12 (2004 Dec) 2063-2069